Table 4.
Review of the response to platinum retreatment in patients who were tested with tNGS (11 cases) and OncoScan® FFPE platform (15 cases)
| ID | Pre-treatment CA125 | Post-treatment CA125 |
CA125 Confirmation | Largest lesion pre -treatment | Largest lesion post-treatment | Treatment Response |
|---|---|---|---|---|---|---|
| 1 | 102.9 | 32.2 | – | SUV 4.54 in pelvis | No PET-CT contrast enhancement | CR |
| 2 | 115 | 62 | 31 | Pleural (72 mm) | Pleural (70 mm) | PR |
| 3 | 40.9 | 20.1 | 17.1 | Peritoneal (31 mm) | Peritonium (26 mm) | SD |
| 4 | 637 | 1143 | – | Liver (45 mm) | Liver (54 mm) | DP |
| 5 | 92.3 | 79 | 24.2 | Peritoneal (63 mm) | Peritonium (47 mm) |
PR |
| 6 | 35 | 18.6 | 0 | SUV 11.0 in liver, 3.2 in adrenal, 8.0 pre-sacral | No PET-CT contrast enhancement | CR |
| 7 | 1174 | 222,9 | 71.5 | Pleural effusion | Pleural effusion resolution* | PR |
| 8 | 258 | 331 | – | SUV 3.0 in peritoneal lesion, 1.9 in epiplon, 3.0 in gut | SUV 11.6 in peritoneal lesion, 3.7 in epiplon, 9.5 in gut | DP |
| 9 | – | – | – | – | Bowel obstruction | DP |
| 10 | 4430 | 1887 | 2180 | Pelvic (101 mm) | Pelvic (90 mm) | PR |
| 11 | 546 | 81.6 | 60 | Pre-sacral (117 mm) | Pre-sacral (106 mm) |
PR |
| 12 | 2600 | 3004 | – | Peritoneal thickening | New hepatic lesion (24 mm) | DP |
| 13 | 32 | 14.2 | 17.6 | Retroperitoneal lesion (40 mm) | Retroperitoneal lesion (40 mm) | SD |
| 14 | – | – | – | – | Bowel obstruction | DP |
| 15 | 52.2 | 94.6 | 185 | – | New brain lesion | DP |
CA125 confirmation: a second CA125 measurement at least two weeks after the post treatment was performed aiming to confirm the treatment response; PET-CT FDG positron emission tomography – compute tomography, SUV standardized uptake value, CR complete response, PR partial response, SD stable disease, DP disease progression
*No surgical procedure was performed between the evaluations